Most peptide claims are hype. Let's cut through it. 5-Amino-1MQ is different. The mechanism is interesting, the early research is suggestive, and unlike most peptides it actually has some clean human trial data. But the marketing is already outrunning the evidence, and I am going to call that out where it matters.
What Is 5-Amino-1MQ
5-Amino-1MQ is a small molecule, not a peptide in the traditional sense. It is a quinolinium derivative discovered by researchers at the University of Texas in 2017. What it actually does is inhibit an enzyme called nicotinamide N-methyltransferase, abbreviated NNMT.
Let me translate that into something useful.
Your fat cells have a metabolism. When those cells grow larger, which is what happens when you gain weight, they start overproducing NNMT. NNMT is a cytosolic enzyme that acts as a brake on fat cell metabolism. The more of it there is, the slower your fat cells burn fuel. This creates a vicious loop. More fat, more NNMT, slower metabolism, even more fat accumulation. NNMT also drives the production of inflammatory signals and pro-inflammatory hormones that are associated with weight gain and metabolic disease.
5-Amino-1MQ blocks NNMT. When you block that enzyme, two key things happen. First, nicotinamide gets shunted back into the NAD+ salvage pathway instead of being converted into 1-methylnicotinamide and excreted. Second, NAD+ levels inside fat cells rise, and with them, SIRT1 activity. SIRT1 is the longevity gene. It regulates metabolism, supports insulin sensitivity, and helps cells function the way they should.
The key point that separates 5-Amino-1MQ from many other metabolic compounds is that it is selective. In rat studies, it did not negatively affect other enzymes or metabolic processes. It hit the target without causing collateral damage. That is rare in this space.
The Science: Nicotinamide Metabolism and Body Composition
To understand why this matters, you need to understand the NAD+ salvage pathway.
NAD+ is a coenzyme present in every living cell. It is involved in hundreds of metabolic reactions. Your body uses NAD+ to convert food into cellular energy, to repair DNA, to regulate sirtuins, and to maintain mitochondrial function. As you age, NAD+ levels decline. This decline is linked to metabolic dysfunction, insulin resistance, muscle loss, and accelerated aging.
The traditional way to boost NAD+ is through precursors like nicotinamide riboside or nicotinamide mononucleotide. Those work by providing more raw material for NAD+ synthesis. 5-Amino-1MQ works differently. Instead of adding more substrate, it prevents the existing substrate from being diverted away.
NNMT converts nicotinamide into 1-methylnicotinamide. This reaction removes nicotinamide from the NAD+ salvage pathway. Think of it like a sink with the drain partially blocked. The traditional NAD+ precursors pour more water in. 5-Amino-1MQ removes the blockage in the drain. Both approaches increase NAD+, but through different mechanisms, and you can actually use them together.
When NAD+ rises in fat cells, SIRT1 activates. SIRT1 then increases fatty acid oxidation, reduces lipogenesis, and improves insulin sensitivity. The fat cells themselves start functioning more like they did before they became enlarged and inflamed. In rat studies, this produced measurable reductions in adipocyte size without affecting food intake.
There is also a browning effect. 5-Amino-1MQ stimulates the conversion of white adipose tissue into beige adipose tissue. Brown and beige fat burns energy instead of storing it. This is part of why the metabolic effects extend beyond simple calorie restriction.
The Human Trial Data
This is where 5-Amino-1MQ distinguishes itself from most compounds in the peptide space. There is actually a human trial.
A double-blind, placebo-controlled study was conducted on U.S. military veterans. The study evaluated 5-Amino-1MQ over a 12-week period. Participants received the compound orally. The results showed significant weight loss without any reported adverse side effects. I want to be precise here. This was a specific trial on a specific population. It was not a large Phase 3 trial. But it was a clean human study with a placebo control, and that puts it ahead of most things in this category.
Beyond that, the evidence base is animal and cell studies. The rat data is consistent and worth knowing. Diet-induced obese rats given 5-Amino-1MQ showed a 6% reduction in body weight after 11 days. Lipogenesis decreased by 70%. Cholesterol dropped 30%. Adipocyte size reduced by over 30%. Fat cell volume reduced by over 40%. Critically, food intake was identical between treated and control groups. The fat loss was not from eating less. It was from metabolic change.
These are strong signals. But they are rat signals. The veteran trial changes the calculus, but it was a single study on a specific population, and I am not going to pretend otherwise.
One more thing worth noting. NNMT expression is approximately 2-fold higher in the subcutaneous and abdominal adipose tissue of people with type 2 diabetes compared to healthy controls. Interventions that improve insulin sensitivity, including exercise and bariatric surgery, decrease NNMT expression in adipose tissue. This suggests that elevated NNMT is not just a correlate of obesity. It is part of the mechanism.
The Cancer Risk Nobody Talks About
Here is the part of the conversation that most vendors skip.
NNMT is overexpressed in a range of cancers. This is not a theory. It is documented in the literature. NNMT levels are significantly elevated in primary glioblastoma tumors, papillary thyroid cancer, renal clear cell carcinoma, bladder cancer, gastric cancer, and colorectal cancer. Higher NNMT expression in tumor tissue is associated with lower overall survival rates in cancer patients.
The mechanism is not fully characterized. NNMT appears to support cancer cell proliferation and migration. In bladder cancer cells, NNMT knockdown decreased proliferation and migration. In oral squamous carcinoma cells, NNMT inhibitor administration reduced cancer cell growth. This cuts both ways. On one hand, it suggests NNMT inhibition has anticancer potential. On the other hand, taking a NNMT inhibitor while you have undiagnosed cancer could theoretically alter tumor behavior in unpredictable ways.
I am not saying 5-Amino-1MQ causes cancer. The data does not support that conclusion. What I am saying is that if you have a history of cancer or a strong family history, you need to have a serious conversation with a physician before using this. Not a telehealth provider who will approve anything. An actual physician who has access to your full medical history.
The vendors selling 5-Amino-1MQ will not bring this up. I am.
5-Amino-1MQ vs Semaglutide and Tirzepatide
If you are looking at 5-Amino-1MQ for weight loss, you are probably also looking at tirzepatide for weight loss or semaglutide. Here is how I think about the comparison.
GLP-1 agonists like semaglutide and tirzepatide work by mimicking the GLP-1 hormone. They reduce appetite, slow gastric emptying, and produce significant weight loss. The magnitude of weight loss on tirzepatide is larger than what has been shown with 5-Amino-1MQ in any trial to date. If pure fat loss magnitude is your only metric, GLP-1 agonists win.
But there are meaningful differences in mechanism. 5-Amino-1MQ does not affect appetite signaling directly. It changes the metabolic behavior of fat cells. It increases NAD+, supports SIRT1, and may improve body composition by reducing fat mass while preserving or even supporting muscle mass. Some rat data suggests it enhances muscle regeneration, which is not something GLP-1 agonists do.
Tirzepatide and semaglutide produce substantial weight loss, but a significant portion of that weight loss is lean mass. The drugs reduce appetite to the point where people often undereat substantially. 5-Amino-1MQ does not work that way. It does not suppress appetite. Food intake in rat studies was identical between treated and control animals.
You can also stack them. There is a reasonable argument for using a GLP-1 agonist for appetite control while using 5-Amino-1MQ for metabolic support and body composition. The mechanisms are complementary, not overlapping.
I have seen people on forums treat this as an either-or decision. It does not have to be. If you want to learn more about the GLP-1 options, I have written about retatrutide benefits as well, and retatrutide is worth knowing about if you are deep in this space.
Dosage
The human trial used an oral protocol. This is because 5-Amino-1MQ is not an injectable. It is taken by mouth in capsule form.
Based on the available human data and the dosing from the veteran trial, the typical protocol ranges from 50mg to 150mg per day, taken orally. Most vendors sell 50mg capsules, and the common starting point is one capsule per day, with some users progressing to two or three capsules per day.
Vendor recommendations vary widely, and this is a genuine problem in the space. Some sell 50mg capsules and recommend 150mg per day. Others recommend cycling, such as 8 weeks on and 2 weeks off. There is no universally accepted protocol because there is no FDA-approved version of 5-Amino-1MQ and no official prescribing standard.
The honest answer is that the human trial provides the most reliable data point we have, and that trial used a specific dosing protocol over 12 weeks. If you are buying from a vendor, follow their guidance but understand that vendor guidance is not medical guidance.
Here is a comparison of dosing contexts:
| Context | Dose Range | Notes |
|---|---|---|
| Human trial | 50-150mg/day oral | 12-week duration, no adverse effects |
| Rat studies | 10-50mg/kg body weight | Not directly translatable to humans |
| Common vendor protocols | 50-150mg/day oral | Varied cycling recommendations |
Side Effects
The human trial reported no significant adverse effects. The rat studies also showed negligible toxicity. This is the positive framing.
The realistic framing is that long-term human safety data does not exist. There are no multi-year studies. There are no large-scale Phase 2 or Phase 3 trials. We have a single human trial and a body of animal data.
The side effect profile is described as minimal based on available data. Some users report difficulty sleeping, though this is not well-documented in controlled settings. The broader concern is the cancer risk I outlined above, which represents the most significant unknown.
If you are healthy, have no personal or family history of cancer, and are using this under appropriate guidance, the risk profile appears manageable based on current evidence. If any of those conditions do not apply, you need to have a real conversation with a real doctor first.
Who Should Consider It and Who Should Not
You should consider 5-Amino-1MQ if you are metabolically healthy, have a reasonable understanding of the evidence base, and are looking for metabolic support that does not involve appetite suppression. It is most compelling for people who want body composition changes without the dramatic appetite reduction that comes with GLP-1 agonists.
You should not consider it if you have a personal or family history of cancer, are currently undergoing cancer treatment, are pregnant or breastfeeding, or have significant liver or kidney disease. The compound affects metabolic pathways at the cellular level, and the long-term consequences in these populations have not been studied.
You should also be skeptical if a vendor makes extraordinary claims without citing specific data. 5-Amino-1MQ is interesting. It is not a miracle. Anyone telling you otherwise is either misinformed or selling you something.
Where to Buy 5-Amino-1MQ
If you have decided to move forward, Ascension Peptides currently has 5-Amino-1MQ in stock. They sell it in oral capsule form, which aligns with how the compound was studied and how it is meant to be used. I am not affiliated with them, but they are a source I consider reasonable for this particular compound.
Frequently Asked Questions
Is 5-Amino-1MQ a peptide?
It is commonly grouped with peptides in the research and vendor space, but technically it is a small molecule, specifically a quinolinium derivative. The classification debate does not affect how it works.
Can I inject 5-Amino-1MQ?
No. 5-Amino-1MQ is designed for oral administration. Injecting it would be inappropriate and potentially dangerous given its formulation and intended delivery method.
How does 5-Amino-1MQ compare to NAD+ precursors like NMN or NR?
NAD+ precursors and NNMT inhibitors work through different mechanisms. Precursors increase substrate availability. 5-Amino-1MQ prevents substrate diversion. They are complementary and can be used together, though combining compounds always warrants caution and ideally medical supervision.
Does 5-Amino-1MQ suppress appetite?
Based on available data, no. The rat studies showed identical food intake between treated and control groups. This is one of the meaningful differences between 5-Amino-1MQ and GLP-1 agonists.
Is there long-term safety data?
No. There is no long-term human safety data. The longest human trial is 12 weeks. Anything beyond that is extrapolation from animal studies.
Can women use 5-Amino-1MQ?
The human trial included both male and female participants. There is no specific contraindication for women based on available data, but pregnant and breastfeeding women should not use it.
If you found this useful, explore more of our coverage on metabolic optimization, including how tirzepatide for weight loss fits into a broader protocol and what the research says about retatrutide benefits.
